CIK 0001787297 · Non-accelerated filer<br>Smaller reporting company
Passage BIO, Inc.
Sign in to watch- Ticker
- PASG
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 822729751
- Phone
- 2678660312
- Business address
- ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA, PA, 19103
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-03-03 | Ratcliffe Liam Director | Conversion | +2,066,630 | 2,066,630 | ||
| 2020-03-03 | Ratcliffe Liam Director | Purchase | +550,000 | $18.00 | $9.9M | 2,616,630 |
| 2020-03-03 | Ratcliffe Liam Director | Purchase | +2,800 | $18.00 | $50K | 2,800 |
| 2020-03-03 | Ratcliffe Liam Director | Conversion · Series B Preferred Stock | −2,066,630 | 0 | ||
| 2020-03-03 | ORBIMED ADVISORS LLC 10% owner | Conversion | +3,721,552 | 4,094,852 | ||
| 2020-03-03 | ORBIMED ADVISORS LLC 10% owner | Conversion | +1,311,469 | 5,406,321 | ||
| 2020-03-03 | ORBIMED ADVISORS LLC 10% owner | Conversion | +541,002 | 5,947,323 | ||
| 2020-03-03 | ORBIMED ADVISORS LLC 10% owner | Conversion · Series A-1 Preferred Stock | −3,721,552 | 0 | ||
| 2020-03-03 | ORBIMED ADVISORS LLC 10% owner | Conversion · Series A-2 Preferred Stock | −1,311,469 | 0 | ||
| 2020-03-03 | ORBIMED ADVISORS LLC 10% owner | Conversion · Series B Preferred Stock | −541,002 | 0 | ||
| 2020-03-03 | Versant Venture Capital VI, L.P. 10% owner | Conversion | +2,977,242 | 2,977,242 | ||
| 2020-03-03 | Versant Venture Capital VI, L.P. 10% owner | Conversion | +1,049,175 | 4,026,417 | ||
| 2020-03-03 | Versant Venture Capital VI, L.P. 10% owner | Conversion | +708,352 | 708,352 | ||
| 2020-03-03 | Versant Venture Capital VI, L.P. 10% owner | Purchase | +225,000 | $18.00 | $4.0M | 933,352 |
| 2020-03-03 | Versant Venture Capital VI, L.P. 10% owner | Conversion · Series A-1 Preferred Stock | −2,977,242 | 0 | ||
| 2020-03-03 | Versant Venture Capital VI, L.P. 10% owner | Conversion · Series A-2 Preferred Stock | −1,049,175 | 0 | ||
| 2020-03-03 | Versant Venture Capital VI, L.P. 10% owner | Conversion · Series B Preferred Stock | −708,352 | 0 | ||
| 2020-03-03 | Frazier Life Sciences IX, L.P. 10% owner | Conversion | +2,977,242 | 2,977,242 | ||
| 2020-03-03 | Frazier Life Sciences IX, L.P. 10% owner | Conversion | +1,049,175 | 4,026,417 | ||
| 2020-03-03 | Frazier Life Sciences IX, L.P. 10% owner | Conversion | +432,802 | 4,459,219 |
Page 11 of 14 · 264 trades